Royalty Pharma plc (RPRX) Q1 2023 Earnings Call Transcript

Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Convention Name Could 9, 2023 8:00 AM ET

Firm Contributors

George Grofik – Senior Vice President, Head-Investor Relations and Communications

Pablo Legorreta – Founder and Chief Govt Officer

Marshall Urist – Govt Vice President, Head-Analysis and Investments

Terry Coyne – Govt Vice President and Chief Monetary Officer

Chris Hite – Govt Vice President and Vice Chairman

Convention Name Contributors

Chris Shibutani – Goldman Sachs

Chris Schott – JPMorgan

Steve Scala – Cowen

Terence Flynn – Morgan Stanley

Susan Chor – Financial institution of America

Mike DiFiore – Evercore ISI

Ash Verma – UBS

Operator

Girls and gents, thanks for standing by. Welcome to the Royalty Pharma First Quarter Earnings Convention Name.

I’d now like to show the decision over to George Grofik, SVP, Head of Investor Relations and Communications. Please go forward, sir.

George Grofik

Good morning and good afternoon to everybody on the decision. Thanks for becoming a member of us to evaluation Royalty Pharma’s first quarter 2023 outcomes. You could find the press launch with our earnings outcomes and slides of this name on the Buyers web page of our web site at royaltypharma.com.

Transferring to Slide 3. I want to remind you that data introduced on this name accommodates forward-looking statements that contain recognized and unknown dangers, uncertainties and different components which will trigger precise outcomes to vary materially from these statements. I refer you to our 10-Okay on file with the SEC for an outline of those dangers. All forward-looking statements are primarily based on data at present out there to Royalty Pharma, and we assume no obligation to replace any such forward-looking statements.

Non-GAAP monetary measures might be used that can assist you perceive our monetary efficiency. The GAAP to non-GAAP reconciliations are offered within the earnings press launch out there on our web site.

And

Back To Top